Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death

Neurobiology of Aging

Volumn 23, Issue 5, 2002, Pages 655-664

  Allan Butterfield, D ^a   Castegna, Alessandra ^a   Lauderback, Christopher M ^a   Drake, Jennifer ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; APOE

Indexed keywords

4 HYDROXYNONENAL; ACROLEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BETA ACTIN; CARBONYL DERIVATIVE; CREATINE KINASE; CYSTEINE; GLUTAMIC ACID; HISTIDINE; LYSINE; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; BRAIN NERVE CELL; BRAIN SYNAPTOSOME; CELL DEATH; ENZYME INHIBITION; HUMAN; IMMUNOPRECIPITATION; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CELL DEATH; HUMANS; LIPID PEROXIDATION; NEURONS;

EID: 0036753272     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(01)00340-2     Document Type: Review

References (105)

1. Aksenov M.Y., Aksenova M.V., Carney J.M., Butterfield D.A. Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Radic. Res. 27:1997;267-281.
2. Atzori L, Dore M, Congiu L. Aspects of allyl alcohol toxicity. Drug Metabol Drug Interact 1989;295-319.
3. Avdulov N.A., Chochina S.V., Igbavboa U., O'Hare O., Schroeder F., Cleary J.P.et al. Amyloid beta-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. J. Neurochem. 68:1997;2086-2091.
4. Balazs L., Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res. 19:1994;1131-1137.
5. Banks W.A., Farr S.A., Butt W., Kumar V.B., Franko M.F., Morley J.E. Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J. Pharmacol. Exp. Ther. 297:2001;1113-1121.
6. Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., Poirier J. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Mol. Brain Res. 68:1999;181-185.
7. Bruce-Keller A., Li Y.J., Lovell M.A., Kraemer P.J., Gary P.S., Brown R.R.et al. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons, and impairs visuo-spatial memory in rats. J. Neuropathol. Exp. Neurol. 57:1998;257-267.
8. Bruce-Keller A.J., Begley J.G., Fu W., Butterfield D.A., Bredesen D.E., Hutchins J.B.et al. Bc1-2 protects isolatedplasma, and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide, and amyloid β-peptide. J. Neurochem. 70:1998;31-39.
9. Bruns C.M., Hubatsch I., Ridderstrom M., Mannervik B., Tainer J.A. Human glutathione transferase A4-4 crystal structures and mutagenesis reveal the basis of high catalytic efficiency with toxic lipid peroxidation products. J. Mol. Biol. 288:1999;427-439.
10. Butterfield D.A. Amyloid-associated free radical oxidative stress, and neurotoxicity: implications for Alzheimer's disease. Chem. Res. Toxicol. 10:1997;495-506.
11. Butterfield D.A., Kanski J. Review: methionine residue 35 is critical for the oxidative stress, and neurotoxic properties of Alzheimer's amyloid β-peptide(1-42). Peptides. 23:2002;1299-1309.
12. Butterfield D.A., Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 122:2001;945-962.
13. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32:2002;1050-1060.
14. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role of amyloid beta-peptide. Trends Mol. Med. 7:2001;548-554.
15. Butterfield D.A., Hensley K., Cole P., Subramaniam R., Aksenov M., Aksenova M.et al. Oxidatively-induced structural alteration of glutamine synthetase assessed by analysis of spin labeled incorporation kinetics: relevance to Alzheimer's disase. J. Neurochem. 68:1997;2451-2457.
16. Butterfield D.A., Hensley K., Harris M., Mattson M., Carney J. Beta-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200:1994;710-715.
17. Butterfield D.A., Stadtman E.R. Protein oxidation processes in aging brain. Adv. Cell. Aging Gerontol. 2:1997;161-191.
18. Butterfield D.A., Yatin S., Varadarajan S., Koppal T. Amyloid β-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease. Methods Enzymol. 309:1999;746-768.
19. Buttini M., Orth M., Bellosta S., Akeefe H., Pitas R.E., Wyss-Coray T.et al. Expression of human apolipoprotein E3 or E4 in the brains of APOE-/- mice: isoform-specific effects on neurodegeneration. J. Neurosci. 19:1999;4867-4880.
20. Calingasan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem. 72:1999;751-756.
21. Curtain C.C., Ali F., Volitakis I., Cherny R.A., Norton R.S., Beyreuther K.et al. Alzheimer's disease amyloid binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276:2001;20466-20473.
22. Esterebauer H., Ramos M. Chemistry and pathophysiology of oxidation of LDL. Rev. Physiol. Biochem. Pharmacol. 127:1996;31-64.
23. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde, and related aldehydes. Free. Radic. Biol. Med. 11:1991;81-128.
24. Gamblin T.C., King M.E., Dawson H., Vitek M.P., Kuret J., Berry R.W. Oxidative regulation of fatty acid induced tau polymerization. Biochemistry. 39:2000;14203-14210.
25. Guan Z., Wang Y., Cairns N.J., Lantos P.L., Dallner G., Sindelar P.J. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 58:1999;740-747.
26. Guo Z.H., Mattson M.P. In vivo 2-deoxyglucose administration preserves glucose and glutamate transport and mitochondrial function in cortical synaptic terminals after exposure to amyloid beta-peptide and iron: evidence for a stress response. Exp. Neurol. 166:2000;173-179.
27. Halliwell B., Gutteridge J.M. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186:1990;1-85.
28. Harris M.E., Carney J.M., Cole P.S., Hensley K., Howard B.J., Martin L.et al. Beta-amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. NeuroReport. 6:1995;1875-1879.
29. +-dependent glutamate uptake in rat hippocampal astrocyte cultures. J. Neurochem. 67:1996;277-286.
30. Hensley K., Hall N.C., Subramaniam R., Cole P., Harris M., Aksenov M.et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65:1995;2146-2156.
31. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F.et al. A model for β-amyloid aggregation, and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:1994;3270-3274.
32. Hockenbery D.M., Oltvai Z.N., Yin X.M., Millima C.L., Korsmeyer S.J. Bc1-2-functions in an antioxidant pathway to prevent apoptosis. Cell. 75:1993;241-251.
33. Jordan J., Galindo M.F., Miller R., Reardon C., Getz G., Ladu M.J. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J. Neurosci. 18:1998;195-204.
34. Kang D.E., Pietrzik C., Baum L., Chevallier N., Merriam D.E., Kounnas M.et al. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 106:2001;1159-1166.
35. Katzman R., Saitoh T. Advances in Alzheimer's disease. FASEB J. 4:1991;278-286.
36. Keller J.N., Mark R.J., Bruce A.J., Blanc E., Rothstein J.D., Uchida K.et al. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience. 80:1997;685-696.
37. Koppal T., Subramaniam R., Drake J., Prasad M.R., Dhillon H., But-terfield B.A. Vitamin E protects against amyloid peptide (25-35)-induced changes in neocortical synaptosomal membrane lipid structure and composition. Brain Res. 786:1998;270-273.
38. Koppal T., Drake J., Yatin S., Jordan B., Varadarajan S., Bettenhausen L.et al. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J. Neurochem. 72:1999;310-317.
39. Koppal T., Drake J., Butterfield D.A. In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochim. Biophys. Acta. 1453:1999;407-411.
40. Kruman I., Bruce-Keller A.J., Bredesen D., Waeg G., Mattson M.P. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 17:1997;5089-5100.
41. Lafon-Cazal M., Pietri S., Culcasi M., Boekaert J. NMDA-dependent superoxide production, and neurotoxicity. Nature. 364:1993;535-537.
42. LaFontaine M.A., Geddes J.W., Banks A., Butterfield D.A. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J. Neurochem. 75:2000;1709-1715.
43. Lauderback C.M., Kanski J., Hackett J.M., Maeda N., Kindy M.S., Butterfield D.A. Apolipoprotein E modulates Alzheimer's Aβ(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res. 924:2002;90-97.
44. Lauderback C.M., Hackett J.M., Huang F., Keller J.M., Szweda L., Markesbery W.R.et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ(1-42). J. Neurochem. 78:2001;413-416.
45. Lauderback C.M., Hackett J., Keller J.N., Varadarajan S., Szweda L., Kindy M.S. Apoliprotein E knock-out synaptosomes are vulnerable to Aβ(1-40)-induced oxidative injury. Biochemistry. 40:2001;2548-2554.
46. Lovell M.A., Ehmann W.D., Butler S.M., Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1995;1594-1601.
47. Lovell M.A., Markesbery W.R. Decreased glutathione transferase in brain and ventricular fluid in Alzheimer's disease. Neurology. 51:1998;1562-1566.
48. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging. 22:2001;187-194.
49. Mahley R. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
50. Maor I., Kaplan M., Hayek T., Vaya J., Hoffman A., Aviram M. Oxidized monocyte-derived macrophages in aortic atherosclerotic lesion from apolipoprotein E-deficient mice and from human carotid artery contain lipid peroxides and oxysterols. Biochem. Biophys. Res. Commun. 269:2000;775-780.
51. Maragakis N.J., Rothstein J.D. Glutamate transporters in neurologic disease. Arch. Neurol. 58:2001;365-370.
52. Marcus D.L., Thomas C., Rodriguez C., Simberkoff K., Tsai T.S., Strafaci J.A.et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neurol. 150:1998;40-44.
53. 2+ homeostasis and cell death. J. Neurosci. 15:1995;6239-6249.
54. Mark R.J., Fuson K.S., May P.C. Characterization of 8-epiprostaglandin F2alpha as a marker of amyloid β-peptide-induced oxidative damage. J. Neurochem. 72:1999;1146-1153.
55. Mark R.J., Lovell M.A., Markesbery M.R., Uchida K., Mattson M.P. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis, and neuronal death induced by amyloid β-peptide. J. Neurochem. 68:1997;255-264.
56. Mark R.J., Pang Z., Geddes J.W., Uchida K., Mattson M.P. Amyloid β-peptide impairs glucose transport in hippocampal, and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17:1997;1046-1054.
57. Markesbery W.R., Lovell M.A. 4-Hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging. 19:1998;33-36.
58. Markesbery W.R. Oxidative stress hypothesis in Alzheimer disease. Free Radic. Biol. Med. 23:1997;134-147.
59. Masliah E., Samuel W., Veinbergs I., Mallory M., Mante M., Saitoh T. Neurodegeneration and cognitive impairment in APOE-deficient mice is ameliorated by infusion of recombinant APOE. Brain Res. 751:1997;307-314.
60. Masliah E., Alford M., DeTeresa R., Mallory M., Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 40:1996;759-766.
61. Mason R.P., Estermeyer J.D., Kelly J.F., Mason P.E. Alzheimer's disease amyloid β peptide (25-35) is localized in the membrane hydrocarbon core: X-ray diffraction analysis. Biochem. Biophys. Res. Commun. 222:1996;78-82.
62. Matthews R.T., Beal M.F. Increased 3-nitrotyrosine in brains of APOE-deficient mice. Brain Res. 718:1996;181-184.
63. Mattson M.P., Keller J.N., Begley J.G. Evidence for synaptic apoptosis. Exp. Neurol. 153:1998;35-48.
64. 31P NMR spectroscopy detects altered phospholipids metabolism in Alzheimer's disease. Can. J. Neurol. Sci. 13:1986;535-539.
65. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity, and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14:1996;55-61.
66. Montine K.S., Olson S.J., Ventkataraman A., Whetsell W., Graham D.G., Montine T.J. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am. J. Path. 150:1997;437-443.
67. Montine K.S., Reich E., Neely M.D., Sidell K.R., Olson S.J., Markesbery W.R.et al. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J. Neuropath. Exp. Neurol. 57:1998;415-425.
68. Montine K.S., Kim P.S., Markesbery W.R., Montine T.J. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J. Neuropathol. Exp. Neurol. 56:1997;866-871.
69. Montine T.J., Markesbery W.R., Zackert W., Sanchez S.T., Roberts L.J., Morrow J.D. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am. J. Pathol. 155:1999;863-868.
70. Montine T.J., Montine K.S., Olson S.J., Graham D.G., Roberts L.J., Morrow J.D.et al. Increased cerebral cortical lipid peroxidation and abnormal phospholipids in aged homozygous APOE-deficient C57BL/6J mice. Exp. Neurol. 158:1999;234-241.
71. Montine T.J., Markesbery W.R., Morrow J.D., Roberts L.J. Cerebrospinal fluid F2 isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 44:1998;410-413.
72. Nigam S., Schewe T. Phospholipase A(2)s, and lipid peroxidation. Biochim. Biophys. Acta. 1488:2000;167-181.
73. Nitsch R.M., Blusztajan J.K., Pittas A.G., Slak B.E., Growdon J.H., Wurtman R.J. Evidence for a membrane defect in Alzhemier disease brain. Proc. Natl. Acad. Sci. USA. 89:1992;1671-1675.
74. Palmer A.M., Burns M.A. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645:1994;338-342.
75. Pedersen W.A., Chan S.L., Mattson M.P. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 74:2000;1426-1433.
76. Pocernich C.B., Cardin A., Racine C., Lauderback C.M., Butterfield D.A. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem. Int. 39:2001;141-149.
77. Pocernich C.B., LaFontaine M., Butterfield D.A. In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem. Int. 36:2000;185-191.
78. Poirier J., Apolipoprotein E. Alzheimer's disease: a role in amyloid catabolism. Ann. N Y Acad. Sci. 924:2000;80-90.
79. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 23:1998;81-88.
80. Praticó D., Rokach J., Tangirala R.K. Brains of aged apolipoprotein E-deficient mice have increased levels of F2-isoprostanes in vivo markers of lipid peroxidation. J. Neurochem. 73:1999;736-741.
81. Ramassamy C., Averill D., Beffert U., Bastianetto S., Theroux L., Lussier-Cacan S.et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic. Biol. Med. 27:1999;544-553.
82. Ramassamy C., Averill D., Beffert U., Theroux L., Lussier-Cacan S., Cohn J.S.et al. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol. Dis. 7:2000;23-37.
83. Reich E.E., Markesbery W.R., Roberts L.J., Swift L.L., Morrow J.D., Montine T.J.et al. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am. J. Pathol. 158:2001;293-297.
84. Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47:1996;387-400.
85. Sayre L.M., Zelasko D.A., Harris P.L., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation products are increased in Alzheimer's disease. J. Neurochem. 68:1997;2092-2097.
86. Schoneich C., Zhao F., Madden K.P., Bobrowski K. Side chain fragmentation of N-terminal threonine or serine residue induced through intramolecular protien transfer to hydroxyl sulfuranyl radical formed at neighboring methionine in dipeptides. J. Am. Chem. Soc. 116:1994;4641-4652.
87. Selkoe D.J. Amyloid β-protein, and the genetics of Alzheimer's disease. J. Biol. Chem. 271:1996;18295-18298.
88. Selley M.L. Determination of the product of lipid peroxidation 4-hydroxy-2-nonenal in clinical samples by gas chromatography-negative ion-chemical ionization mass spectroscopy of the O-pentafluorobenzyl oxime. J. Chromatogr. B. Biomed. Sci. Appl. 691:1997;263-268.
89. Sheng H., Laskowitz D.T., Bennett E., Schmechel D.E., Bart R.D., Saunders A.M.et al. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J. Cereb. Blood Flow Metab. 18:1998;361-366.
90. Subbarao K.V., Richardson J.S., Ang L.C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. Neurology. 45:1990;1594-1601.
91. Subramaniam R., Roediger F., Jordan B., Mattson M.P., Keller J.N., Waeg G.et al. The lipid peroxidation product 4-hydroxy-2-trans-nonenal alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 69:1997;1161-1169.
92. Takaoma A., Miyatake F., Matsuno S., Ishii K., Nagase S., Sahara N.et al. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology. 54:2000;2319-2321.
93. Uchida K. Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc. Med. 9:1999;109-113.
94. Uchida H., Stadtman E.R. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc. Natl. Acad. Sci. USA. 89:1992;4544-4589.
95. Van Uden E., Sagara Y., Van Uden J., Orlando R., Mallory M., Rockernstein E.et al. A protective role of the low density lipoprotein receptor-related protein against beta-amyloid beta-protein toxicity. J. Biol. Chem. 275:2000;30525-30530.
96. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress, and neurotoxicity. J. Struct. Biol. 130:2000;184-208.
97. Varadarajan S., Kanski J., Aksenova M., Lauderback C.M., Butterfield D.A. The mechanism of oxidative stress and neurotoxicity of Alzheimer's Aβ(1-42) is different from that of Aβ(25-35). J. Am. Chem. Soc. 123:2001;5625-5631.
98. Varadarajan S., Yatin S., Kanski J., Jahanshahi F., Butterfield D.A. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. Brain Res. Bull. 50:1999;133-141.
99. Yang D.S., Small D.H., Seydel U., Smith J.D., Hallmayer J., Gandy S.E.et al. Apolipoprotein E promotes the binding, and uptake of β-amyloid into chinese hamster ovary cells in an isoform-specific manner. Neuroscience. 90:1999;1217-1226.
100. Yatin S.M., Varadarajan S., Link C.D., Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide(1-42). Neurobiol. Aging. 20:1999;325-330.
101. Butterfield DA, Pocernich CB, Drake J. Elevated gutathione as a therapeutic strategy in Alzheimer's disease. Drug Discovery Res, 2002; in press.
102. Kanski J., Aksenova M., Schoneich C., Butterfield D.A. Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid β-peptide (1-42). Free Radic. Biol. Med. 32:2002;1205-1211.
103. Kanski J., Aksenova M., Butterfield D.A. The hydrophobic environment of Met35 of Alzheimer's Aβ(1-42) is important for the neurotoxic and oxidative properties of the peptide. Neurotoxicity Res. 4:2002;219-223.
104. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33:2002;562-571.
105. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, α-enolase, and heat shock cognate 71. J Neurochem, 2002; in press.